53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma

T. Drake; E. H. Tan; A. Georgakopoulou; S. May; M. Mueller; S. Horrigan; K. Holloway; J. Chang; R. Aras; T. Bird

doi:10.1016/S0959-8049(22)00852-8

53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma

T. Drake
, E. H. Tan
, A. Georgakopoulou
, S. May
, M. Mueller
, S. Horrigan
, K. Holloway
, J. Chang
, R. Aras
, T. Bird

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S19
Journal	European Journal of Cancer
Volume	174
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/S0959-8049(22)00852-8
Publication status	Published - 28 Oct 2022
Event	34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Barcelona, Spain Duration: 26 Oct 2022 → 28 Oct 2022 https://www.eortc.org/event/34th-eortc-nci-aacr-symposium/

Access to Document

10.1016/S0959-8049(22)00852-8

Cite this

Drake, T., Tan, E. H., Georgakopoulou, A., May, S., Mueller, M., Horrigan, S., Holloway, K., Chang, J., Aras, R., & Bird, T. (2022). 53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma. European Journal of Cancer, 174(Supplement 1), S19. https://doi.org/10.1016/S0959-8049(22)00852-8

@article{6063fbf810384cecbdb00f050f76e4c9,

title = "53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma",

author = "T. Drake and Tan, \{E. H.\} and A. Georgakopoulou and S. May and M. Mueller and S. Horrigan and K. Holloway and J. Chang and R. Aras and T. Bird",

year = "2022",

month = oct,

day = "28",

doi = "10.1016/S0959-8049(22)00852-8",

language = "English",

volume = "174",

pages = "S19",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier",

number = "Supplement 1",

note = "34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics ; Conference date: 26-10-2022 Through 28-10-2022",

url = "https://www.eortc.org/event/34th-eortc-nci-aacr-symposium/",

}

Drake, T, Tan, EH, Georgakopoulou, A, May, S, Mueller, M, Horrigan, S, Holloway, K, Chang, J, Aras, R & Bird, T 2022, '53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma', European Journal of Cancer, vol. 174, no. Supplement 1, pp. S19. https://doi.org/10.1016/S0959-8049(22)00852-8

53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma. / Drake, T.; Tan, E. H.; Georgakopoulou, A. et al.
In: European Journal of Cancer, Vol. 174, No. Supplement 1, 28.10.2022, p. S19.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - 53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma

AU - Drake, T.

AU - Tan, E. H.

AU - Georgakopoulou, A.

AU - May, S.

AU - Mueller, M.

AU - Horrigan, S.

AU - Holloway, K.

AU - Chang, J.

AU - Aras, R.

AU - Bird, T.

PY - 2022/10/28

Y1 - 2022/10/28

UR - https://www.scopus.com/pages/publications/85140462366

U2 - 10.1016/S0959-8049(22)00852-8

DO - 10.1016/S0959-8049(22)00852-8

M3 - Meeting abstract

AN - SCOPUS:85140462366

SN - 0959-8049

VL - 174

SP - S19

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Supplement 1

T2 - 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Y2 - 26 October 2022 through 28 October 2022

ER -

53 (PB043) - The TBL1 inhibitor, Tegavivint, suppresses tumour growth and enhances T-cell infiltration in preclinical murine β-Catenin mutant hepatocellular carcinoma

Access to Document

Other files and links

Cite this